FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1946-1952 June 29, 2000 Number 26 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related to their inhibition of cyclooxygenase-2.

Methods We studied the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on colorectal polyps in patients with familial adenomatous polyposis. In a double-blind, placebo-controlled study, we randomly assigned 77 patients to treatment with celecoxib (100 or 400 mg twice daily) or placebo for six months. Patients underwent endoscopy at the beginning and end of the study. We determined the number and size of polyps from photographs and videotapes; the response to treatment was expressed as the mean percent change from base line.

Results At base line, the mean (±SD) number of polyps in focal areas where polyps were counted was 15.5±13.4 in the 15 patients assigned to placebo, 11.5±8.5 in the 32 patients assigned to 100 mg of celecoxib twice a day, and 12.3±8.2 in the 30 patients assigned to 400 mg of celecoxib twice a day (P=0.66 for the comparison among groups). After six months, the patients receiving 400 mg of celecoxib twice a day had a 28.0 percent reduction in the mean number of colorectal polyps (P=0.003 for the comparison with placebo) and a 30.7 percent reduction in the polyp burden (the sum of polyp diameters) (P=0.001), as compared with reductions of 4.5 and 4.9 percent, respectively, in the placebo group. The improvement in the extent of colorectal polyposis in the group receiving 400 mg twice a day was confirmed by a panel of endoscopists who reviewed the videotapes. The reductions in the group receiving 100 mg of celecoxib twice a day were 11.9 percent (P=0.33 for the comparison with placebo) and 14.6 percent (P=0.09), respectively. The incidence of adverse events was similar among the groups.

Conclusions In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colorectal polyps.

Source Information

From the University of Texas M.D. Anderson Cancer Center, Houston (G.S., P.M.L., N.W., Y.S., T.F., L.-K.S., B.L.); the Imperial Cancer Research Fund, St. Mark's Hospital, London (R.K.S.P., M.H.W., B.S.); the National Cancer Institute, Bethesda, Md. (E.H.); and G.D. Searle, Skokie, Ill. (G.B.G.).

Address reprint requests to Dr. Steinbach at the University of Texas M.D. Anderson Cancer Center, Division of Cancer Prevention, Box 203, 1515 Holcombe Blvd., Houston, TX 77030, or at gsteinb{at}aol.com.

Full Text of this Article

This article has been cited by other articles:

• Wirth, L. J., Krane, J. F., Li, Y., Othus, M., Moran, A. E., Dorfman, D. M., Norris, C. M. Jr, Goguen, L., Posner, M. R., Haddad, R. I., Bertagnolli, M. M. (2008). A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions. Cancer Prevention Research 1: 339-348 [Abstract] [Full Text]  
• Hughes, D., Otani, T., Yang, P., Newman, R. A., Yantiss, R. K., Altorki, N. K., Port, J. L., Yan, M., Markowitz, S. D., Mazumdar, M., Tai, H.-H., Subbaramaiah, K., Dannenberg, A. J. (2008). NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase Regulates Levels of Bioactive Lipids in Non-Small Cell Lung Cancer. Cancer Prevention Research 1: 241-249 [Abstract] [Full Text]  
• Arber, N. (2008). Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point. Cancer Epidemiol. Biomarkers Prev. 17: 1852-1857 [Abstract] [Full Text]  
• Jankowski, J., Hunt, R. (2008). Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint. Cancer Epidemiol. Biomarkers Prev. 17: 1858-1861 [Abstract] [Full Text]  
• Girnun, G. D., Howe, L. R., Manne, S., Mao, J. T., Reid, M. E., Szabo, E. (2008). Meeting Report: Sixth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prevention Research 1: 146-149 [Abstract] [Full Text]  
• Markowitz, S. D. (2008). Colorectal Neoplasia Goes with the Flow: Prostaglandin Transport and Termination. Cancer Prevention Research 1: 77-79 [Full Text]  
• Cho, N. L., Redston, M., Zauber, A. G., Carothers, A. M., Hornick, J., Wilton, A., Sontag, S., Nishioka, N., Giardiello, F. M., Saltzman, J. R., Gostout, C., Eagle, C. J., Hawk, E. T., Bertagnolli, M. M. (2008). Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial. Cancer Prevention Research 1: 21-31 [Abstract] [Full Text]  
• Kohne, C.-H., De Greve, J., Hartmann, J. T., Lang, I., Vergauwe, P., Becker, K., Braumann, D., Joosens, E., Muller, L., Janssens, J., Bokemeyer, C., Reimer, P., Link, H., Spath-Schwalbe, E., Wilke, H.-J., Bleiberg, H., Van Den Brande, J., Debois, M., Bethe, U., Van Cutsem, E. (2008). Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19: 920-926 [Abstract] [Full Text]  
• Vasen, H F A, Moslein, G, Alonso, A, Aretz, S, Bernstein, I, Bertario, L, Blanco, I, Bulow, S, Burn, J, Capella, G, Colas, C, Engel, C, Frayling, I, Friedl, W, Hes, F J, Hodgson, S, Jarvinen, H, Mecklin, J-P, Moller, P, Myrhoi, T, Nagengast, F M, Parc, Y, Phillips, R, Clark, S K, de Leon, M P., Renkonen-Sinisalo, L, Sampson, J R, Stormorken, A, Tejpar, S, Thomas, H J W, Wijnen, J (2008). Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57: 704-713 [Abstract] [Full Text]  
• Fidler, M. J., Argiris, A., Patel, J. D., Johnson, D. H., Sandler, A., Villaflor, V. M., Coon, J. IV, Buckingham, L., Kaiser, K., Basu, S., Bonomi, P. (2008). The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib. Clin. Cancer Res. 14: 2088-2094 [Abstract] [Full Text]  
• Papadimitrakopoulou, V. A., William, W. N. Jr., Dannenberg, A. J., Lippman, S. M., Lee, J. J., Ondrey, F. G., Peterson, D. E., Feng, L., Atwell, A., El-Naggar, A. K., Nathan, C.-A., Helman, J. I., Du, B., Yueh, B., Boyle, J. O. (2008). Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions. Clin. Cancer Res. 14: 2095-2101 [Abstract] [Full Text]  
• Dirix, L. Y., Ignacio, J., Nag, S., Bapsy, P., Gomez, H., Raghunadharao, D., Paridaens, R., Jones, S., Falcon, S., Carpentieri, M., Abbattista, A., Lobelle, J.-P. (2008). Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib. JCO 26: 1253-1259 [Abstract] [Full Text]  
• Edelman, M. J., Watson, D., Wang, X., Morrison, C., Kratzke, R. A., Jewell, S., Hodgson, L., Mauer, A. M., Gajra, A., Masters, G. A., Bedor, M., Vokes, E. E., Green, M. J. (2008). Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy--Cancer and Leukemia Group B Trial 30203. JCO 26: 848-855 [Abstract] [Full Text]  
• Dougan, M., Dranoff, G. (2008). Inciting inflammation: the RAGE about tumor promotion. J. Exp. Med. 205: 267-270 [Abstract] [Full Text]  
• Nam, S. Y., Kim, J. S., Kim, J. M., Lee, J. Y., Kim, N., Jung, H. C., Song, I. S. (2008). DA-6034, a Derivative of Flavonoid, Prevents and Ameliorates Dextran Sulfate Sodium-Induced Colitis and Inhibits Colon Carcinogenesis. Exp. Biol. Med. 233: 180-191 [Abstract] [Full Text]  
• Choi, S., Myers, J.N. (2008). Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy. J. Dent. Res. 87: 14-32 [Abstract] [Full Text]  
• Feng, Y., Neale, J. R., Doll, M. A., Hein, D. W. (2008). Chemoprevention of Arylamine-Induced Colorectal Aberrant Crypts. Exp. Biol. Med. 233: 71-75 [Abstract] [Full Text]  
• Hollingshead, H. E., Borland, M. G., Billin, A. N., Willson, T. M., Gonzalez, F. J., Peters, J. M. (2008). Ligand activation of peroxisome proliferator-activated receptor-{beta}/{delta} (PPAR{beta}/{delta}) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29: 169-176 [Abstract] [Full Text]  
• Beliveau, R., Gingras, D. (2007). Role of nutrition in preventing cancer. cfp 53: 1905-1911 [Abstract] [Full Text]  
• Izzo, J. G., Ajani, J. A. (2007). Thinking In and Out of the Box When It Comes to Gastric Cancer and Cyclooxygenase-2. JCO 25: 4865-4867 [Full Text]  
• Chu, D. Z. J., Gibson, G., David, D., Yen, Y. (2007). The Surgeon's Role in Cancer Prevention. The Model in Colorectal Carcinoma. Ann. Surg. Oncol. 14: 3054-3069 [Abstract] [Full Text]  
• Chai, C.-Y., Huang, Y.-C., Hung, W.-C., Kang, W.-Y., Chen, W.-T. (2007). Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells. Mutagenesis 22: 403-408 [Abstract] [Full Text]  
• Iwase, N., Higuchi, T., Gonda, T., Kobayashi, H., Uetake, H., Enomoto, M., Sugihara, K. (2007). The Effect of Meloxicam, a Selective COX-2 Inhibitor, on the Microvasculature of Small Metastatic Liver Tumors in Rats. Jpn J Clin Oncol 37: 673-678 [Abstract] [Full Text]  
• Marshall, J.-C. A., Fernandes, B. F., Di Cesare, S., Maloney, S. C., Logan, P. T., Antecka, E., Burnier, M. N. Jr (2007). The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis 28: 2053-2058 [Abstract] [Full Text]  
• Brown, P. H. (2007). Chemoprevention Clinical Trials: It Is Time to Turn Success into Progress. Cancer Epidemiol. Biomarkers Prev. 16: 1531-1532 [Full Text]  
• Holt, A. P, Adams, D. H (2007). Complex roles of cyclo-oxygenase 2 in hepatitis. Gut 56: 903-904 [Full Text]  
• Xu, K., Shu, H.-K. G. (2007). EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase-Dependent Activation of the Sp1/Sp3 Transcription Factors in Human Gliomas. Cancer Res. 67: 6121-6129 [Abstract] [Full Text]  
• Salinas, G., Rangasetty, U. C., Uretsky, B. F., Birnbaum, Y. (2007). The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame. J CARDIOVASC PHARMACOL THER 12: 98-111 [Abstract]  
• Chan, A. T., Ogino, S., Fuchs, C. S. (2007). Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. NEJM 356: 2131-2142 [Abstract] [Full Text]  
• Bock, J. M., Menon, S. G., Sinclair, L. L., Bedford, N. S., Goswami, P. C., Domann, F. E., Trask, D. K. (2007). Celecoxib Toxicity Is Cell Cycle Phase Specific. Cancer Res. 67: 3801-3808 [Abstract] [Full Text]  
• Subbaramaiah, K., Dannenberg, A. J. (2007). Cyclooxygenase-2 Transcription Is Regulated by Human Papillomavirus 16 E6 and E7 Oncoproteins: Evidence of a Corepressor/Coactivator Exchange. Cancer Res. 67: 3976-3985 [Abstract] [Full Text]  
• Heath, E. I., Canto, M. I., Piantadosi, S., Montgomery, E., Weinstein, W. M., Herman, J. G., Dannenberg, A. J., Yang, V. W., Shar, A. O., Hawk, E., Forastiere, A. A. (2007). Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial. JNCI J Natl Cancer Inst 99: 545-557 [Abstract] [Full Text]  
• Yang, W.-L., Cai, K. Q., Smedberg, J. L., Smith, E. R., Klein-Szanto, A., Hamilton, T. C., Xu, X.-X. (2007). A Reduction of Cyclooxygenase 2 Gene Dosage Counters the Ovarian Morphological Aging and Tumor Phenotype in Wv Mice. Am. J. Pathol. 170: 1325-1336 [Abstract] [Full Text]  
• Shureiqi, I., Zuo, X., Broaddus, R., Wu, Y., Guan, B., Morris, J. S., Lippman, S. M. (2007). The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J. 21: 743-753 [Abstract] [Full Text]  
• Hawk, E., Viner, J. L. (2007). The Adenoma Prevention with Celecoxib and Prevention of Colorectal Sporadic Adenomatous Polyps Trials: Stepping Stones to Progress. Cancer Epidemiol. Biomarkers Prev. 16: 185-187 [Full Text]  
• Andre, T, Tournigand, C, Mineur, L, Fellague-Chebra, R, Flesch, M, Mabro, M, Hebbar, M, Postel Vinay, S, Bidard, F., Louvet, C, de Gramont, A (2007). Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 18: 77-81 [Abstract] [Full Text]  
• Bises, G., Bajna, E., Manhardt, T., Gerdenitsch, W., Kallay, E., Cross, H. S. (2007). Gender-Specific Modulation of Markers for Premalignancy by Nutritional Soy and Calcium in the Mouse Colon. J. Nutr. 137: 211S-215S [Abstract] [Full Text]  
• Jimeno, A., Amador, M. L., Kulesza, P., Wang, X., Rubio-Viqueira, B., Zhang, X., Chan, A., Wheelhouse, J., Kuramochi, H., Tanaka, K., Danenberg, K., Messersmith, W. A., Almuete, V., Hruban, R. H., Maitra, A., Yeo, C. J., Hidalgo, M. (2006). Assessment of celecoxib pharmacodynamics in pancreatic cancer. Molecular Cancer Therapeutics 5: 3240-3247 [Abstract] [Full Text]  
• Gogas, H, Polyzos, A, Stavrinidis, I, Frangia, K, Tsoutsos, D, Panagiotou, P, Markopoulos, C, Papadopoulos, O, Pectasides, D, Mantzourani, M, Middleton, M, Vaiopoulos, G, Fountzilas, G (2006). Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 17: 1835-1841 [Abstract] [Full Text]  
• Chung, D. C., Maher, M. M., Faquin, W. C. (2006). Case 37-2006 -- A 19-Year-Old Woman with Thyroid Cancer and Lower Gastrointestinal Bleeding. NEJM 355: 2349-2357 [Full Text]  
• Cai, Q., Gao, Y.-T., Chow, W.-H., Shu, X.-O., Yang, G., Ji, B.-T., Wen, W., Rothman, N., Li, H.-L., Morrow, J. D., Zheng, W. (2006). Prospective Study of Urinary Prostaglandin E2 Metabolite and Colorectal Cancer Risk. JCO 24: 5010-5016 [Abstract] [Full Text]  
• Soo, R., Wu, J, Aggarwal, A, Tao, Q, Hsieh, W, Putti, T, Tan, K., Soon, W., Lai, Y., Mow, B, Hsu, S, Loh, K., Tan, L, Tan, P, Goh, B-C (2006). Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 17: 1625-1630 [Abstract] [Full Text]  
• Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G., Gagel, R. F., Weitzel, J., Morrow, M., Weber, B. L., Giardiello, F., Rodriguez-Bigas, M. A., Church, J., Gruber, S., Offit, K. (2006). ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. JCO 24: 4642-4660 [Abstract] [Full Text]  
• Cardiff, R. D., Anver, M. R., Boivin, G. P., Bosenberg, M. W., Maronpot, R. R., Molinolo, A. A., Nikitin, A. Y., Rehg, J. E., Thomas, G. V., Russell, R. G., Ward, J. M. (2006). Precancer in Mice: Animal Models Used to Understand, Prevent, and Treat Human Precancers. Toxicol Pathol 34: 699-707 [Abstract] [Full Text]  
• Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G., Gagel, R. F., Weitzel, J., Morrow, M., Weber, B. L., Giardiello, F., Rodriguez-Bigas, M. A., Church, J., Gruber, S., Offit, K. (2006). ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Ann. Surg. Oncol. 13: 1296-1321 [Abstract] [Full Text]  
• Schroeder, C. P., Kadara, H., Lotan, D., Woo, J. K., Lee, H.-Y., Hong, W. K., Lotan, R. (2006). Involvement of Mitochondrial and Akt Signaling Pathways in Augmented Apoptosis Induced by a Combination of Low Doses of Celecoxib and N-(4-Hydroxyphenyl) Retinamide in Premalignant Human Bronchial Epithelial Cells. Cancer Res. 66: 9762-9770 [Abstract] [Full Text]  
• Borthwick, G. M., Johnson, A. S., Partington, M., Burn, J., Wilson, R., Arthur, H. M. (2006). Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J. 20: 2009-2016 [Abstract] [Full Text]  
• Allison, M., Garland, C., Chlebowski, R., Criqui, M., Langer, R., Wu, L., Roy, H., McTiernan, A., Kuller, L., for the Women's Health Initiative Investigators, (2006). The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women. Am J Epidemiol 164: 567-575 [Abstract] [Full Text]  
• Solomon, S. D., Pfeffer, M. A., McMurray, J. J.V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., Bertagnolli, M. M., Arber, N., Wittes, J., for the APC and PreSAP Trial Investigators, (2006). Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas. Circulation 114: 1028-1035 [Abstract] [Full Text]  
• Lou, J., Fatima, N., Xiao, Z., Stauffer, S., Smythers, G., Greenwald, P., Ali, I. U. (2006). Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.. Cancer Epidemiol. Biomarkers Prev. 15: 1598-1606 [Abstract] [Full Text]  
• Buckstein, R., Kerbel, R. S., Shaked, Y., Nayar, R., Foden, C., Turner, R., Lee, C. R., Taylor, D., Zhang, L., Man, S., Baruchel, S., Stempak, D., Bertolini, F., Crump, M. (2006). High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma. Clin. Cancer Res. 12: 5190-5198 [Abstract] [Full Text]  
• Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., Tang, J., Rosenstein, R. B., Wittes, J., Corle, D., Hess, T. M., Woloj, G. M., Boisserie, F., Anderson, W. F., Viner, J. L., Bagheri, D., Burn, J., Chung, D. C., Dewar, T., Foley, T. R., Hoffman, N., Macrae, F., Pruitt, R. E., Saltzman, J. R., Salzberg, B., Sylwestrowicz, T., Gordon, G. B., Hawk, E. T., the APC Study Investigators, (2006). Celecoxib for the prevention of sporadic colorectal adenomas.. NEJM 355: 873-884 [Abstract] [Full Text]  
• Mazhar, D., Ngan, S. (2006). C-reactive protein and colorectal cancer.. QJM 99: 555-559 [Full Text]  
• Eisinger, A. L., Nadauld, L. D., Shelton, D. N., Peterson, P. W., Phelps, R. A., Chidester, S., Stafforini, D. M., Prescott, S. M., Jones, D. A. (2006). The Adenomatous Polyposis Coli Tumor Suppressor Gene Regulates Expression of Cyclooxygenase-2 by a Mechanism That Involves Retinoic Acid. J. Biol. Chem. 281: 20474-20482 [Abstract] [Full Text]  
• Swamy, M. V., Patlolla, J. M.R., Steele, V. E., Kopelovich, L., Reddy, B. S., Rao, C. V. (2006). Chemoprevention of Familial Adenomatous Polyposis by Low Doses of Atorvastatin and Celecoxib Given Individually and in Combination to APCMin Mice.. Cancer Res. 66: 7370-7377 [Abstract] [Full Text]  
• Glebov, O. K., Rodriguez, L. M., Lynch, P., Patterson, S., Lynch, H., Nakahara, K., Jenkins, J., Cliatt, J., Humbyrd, C.-J., DeNobile, J., Soballe, P., Gallinger, S., Buchbinder, A., Gordon, G., Hawk, E., Kirsch, I. R. (2006). Celecoxib treatment alters the gene expression profile of normal colonic mucosa.. Cancer Epidemiol. Biomarkers Prev. 15: 1382-1391 [Abstract] [Full Text]  
• Kaidi, A., Qualtrough, D., Williams, A. C., Paraskeva, C. (2006). Direct Transcriptional Up-regulation of Cyclooxygenase-2 by Hypoxia-Inducible Factor (HIF)-1 Promotes Colorectal Tumor Cell Survival and Enhances HIF-1 Transcriptional Activity during Hypoxia.. Cancer Res. 66: 6683-6691 [Abstract] [Full Text]  
• Carothers, A. M., Moran, A. E., Cho, N. L., Redston, M., Bertagnolli, M. M. (2006). Changes in Antitumor Response in C57BL/6J-Min/+ Mice during Long-term Administration of a Selective Cyclooxygenase-2 Inhibitor.. Cancer Res. 66: 6432-6438 [Abstract] [Full Text]  
• Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., Papadimitrakopoulou, V. A., Lotan, R., Aggarwal, B. B., Bresalier, R. S., Kim, J., Arun, B., Lu, K. H., Thomas, M. E., Rhodes, H. E., Brewer, M. A., Follen, M., Shin, D. M., Parnes, H. L., Siegfried, J. M., Evans, A. A., Blot, W. J., Chow, W.-H., Blount, P. L., Maley, C. C., Wang, K. K., Lam, S., Lee, J. J., Dubinett, S. M., Engstrom, P. F., Meyskens, F. L. Jr., O'Shaughnessy, J., Hawk, E. T., Levin, B., Nelson, W. G., Hong, W. K., for the AACR Task Force on Cancer Prevention, (2006). Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward. Clin. Cancer Res. 12: 3661-3697 [Abstract] [Full Text]  
• Grosch, S., Maier, T. J., Schiffmann, S., Geisslinger, G. (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.. JNCI J Natl Cancer Inst 98: 736-747 [Abstract] [Full Text]  
• Milano, M, Guerin, O (2006). Recent advances in targeted therapies for colorectal cancer. J Oncol Pharm Pract 12: 69-73 [Abstract]  
• Mrozek, E., Kloos, R. T., Ringel, M. D., Kresty, L., Snider, P., Arbogast, D., Kies, M., Munden, R., Busaidy, N., Klein, M. J., Sherman, S. I., Shah, M. H. (2006). Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 91: 2201-2204 [Abstract] [Full Text]  
• Reckamp, K. L., Krysan, K., Morrow, J. D., Milne, G. L., Newman, R. A., Tucker, C., Elashoff, R. M., Dubinett, S. M., Figlin, R. A. (2006). A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.. Clin. Cancer Res. 12: 3381-3388 [Abstract] [Full Text]  
• Yiu, G. K., Toker, A. (2006). NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2. J. Biol. Chem. 281: 12210-12217 [Abstract] [Full Text]  
• Reddy, B. S., Wang, C. X., Kong, A.-N., Khor, T. O., Zheng, X., Steele, V. E., Kopelovich, L., Rao, C. V. (2006). Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats.. Cancer Res. 66: 4542-4546 [Abstract] [Full Text]  
• Dey, M., Ribnicky, D., Kurmukov, A. G., Raskin, I. (2006). In Vitro and in Vivo Anti-Inflammatory Activity of a Seed Preparation Containing Phenethylisothiocyanate. J. Pharmacol. Exp. Ther. 317: 326-333 [Abstract] [Full Text]  
• Souaze, F., Viardot-Foucault, V., Roullet, N., Toy-Miou-Leong, M., Gompel, A., Bruyneel, E., Comperat, E., Faux, M. C, Mareel, M., Rostene, W., Flejou, J.-F., Gespach, C., Forgez, P. (2006). Neurotensin receptor 1 gene activation by the Tcf/{beta}-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 27: 708-716 [Abstract] [Full Text]  
• Pruthi, R. S., Derksen, J. E., Moore, D., Carson, C. C., Grigson, G., Watkins, C., Wallen, E. (2006). Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy.. Clin. Cancer Res. 12: 2172-2177 [Abstract] [Full Text]  
• Lippman, S. M., Lee, J. J. (2006). Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.. Cancer Res. 66: 2893-2903 [Abstract] [Full Text]  
• Castells, A., Paya, A., Alenda, C., Rodriguez-Moranta, F., Agrelo, R., Andreu, M., Pinol, V., Castellvi-Bel, S., Jover, R., Llor, X., Pons, E., Elizalde, J. I., Bessa, X., Alcedo, J., Salo, J., Medina, E., Naranjo, A., Esteller, M., Pique, J. M., for the Gastrointestinal Oncology Group of the Spa, (2006). Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency.. Clin. Cancer Res. 12: 1686-1692 [Abstract] [Full Text]  
• Chen, T., Hwang, H., Rose, M. E., Nines, R. G., Stoner, G. D. (2006). Chemopreventive Properties of Black Raspberries in N-Nitrosomethylbenzylamine-Induced Rat Esophageal Tumorigenesis: Down-regulation of Cyclooxygenase-2, Inducible Nitric Oxide Synthase, and c-Jun.. Cancer Res. 66: 2853-2859 [Abstract] [Full Text]  
• Tanaka, S., Haruma, K., Yoshihara, M., Kajiyama, G., Kira, K., Amagase, H., Chayama, K. (2006). Aged Garlic Extract Has Potential Suppressive Effect on Colorectal Adenomas in Humans. J. Nutr. 136: 821S-826S [Abstract] [Full Text]  
• Holla, V. R., Mann, J. R., Shi, Q., DuBois, R. N. (2006). Prostaglandin E2 Regulates the Nuclear Receptor NR4A2 in Colorectal Cancer. J. Biol. Chem. 281: 2676-2682 [Abstract] [Full Text]  
• D'Orazi, G., Sciulli, M. G., Di Stefano, V., Riccioni, S., Frattini, M., Falcioni, R., Bertario, L., Sacchi, A., Patrignani, P. (2006). Homeodomain-Interacting Protein Kinase-2 Restrains Cytosolic Phospholipase A2-Dependent Prostaglandin E2 Generation in Human Colorectal Cancer Cells. Clin. Cancer Res. 12: 735-741 [Abstract] [Full Text]  
• Tanaka, S, Tatsuguchi, A, Futagami, S, Gudis, K, Wada, K, Seo, T, Mitsui, K, Yonezawa, M, Nagata, K, Fujimori, S, Tsukui, T, Kishida, T, Sakamoto, C (2006). Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 55: 54-61 [Abstract] [Full Text]  
• Wang, D, DuBois, R N (2006). PROSTAGLANDINS AND CANCER. Gut 55: 115-122 [Full Text]  
• Martin, S., Phillips, D. C., Szekely-Szucs, K., Elghazi, L., Desmots, F., Houghton, J. A. (2005). Cyclooxygenase-2 Inhibition Sensitizes Human Colon Carcinoma Cells to TRAIL-Induced Apoptosis through Clustering of DR5 and Concentrating Death-Inducing Signaling Complex Components into Ceramide-Enriched Caveolae. Cancer Res. 65: 11447-11458 [Abstract] [Full Text]  
• Shureiqi, I., Wu, Y., Chen, D., Yang, X. L., Guan, B., Morris, J. S., Yang, P., Newman, R. A., Broaddus, R., Hamilton, S. R., Lynch, P., Levin, B., Fischer, S. M., Lippman, S. M. (2005). The Critical Role of 15-Lipoxygenase-1 in Colorectal Epithelial Cell Terminal Differentiation and Tumorigenesis. Cancer Res. 65: 11486-11492 [Abstract] [Full Text]  
• Tanaka, H., Fujita, N., Tsuruo, T. (2005). 3-Phosphoinositide-dependent Protein Kinase-1-mediated I{kappa}B Kinase {beta} (IKKB) Phosphorylation Activates NF-{kappa}B Signaling. J. Biol. Chem. 280: 40965-40973 [Abstract] [Full Text]  
• Cui, W., Yu, C.-H., Hu, K.-Q. (2005). In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells. Clin. Cancer Res. 11: 8213-8221 [Abstract] [Full Text]  
• Souza, R. F., Spechler, S. J. (2005). Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach. CA Cancer J Clin 55: 334-351 [Abstract] [Full Text]  
• Hawkey, C J (2005). COX-2 chronology. Gut 54: 1509-1514 [Abstract] [Full Text]  
• Hisamuddin, I. M., Wehbi, M. A., Schmotzer, B., Easley, K. A., Hylind, L. M., Giardiello, F. M., Yang, V. W. (2005). Genetic Polymorphisms of Flavin Monooxygenase 3 in Sulindac-Induced Regression of Colorectal Adenomas in Familial Adenomatous Polyposis. Cancer Epidemiol. Biomarkers Prev. 14: 2366-2369 [Abstract] [Full Text]  
• Mazhar, D., Gillmore, R., Waxman, J. (2005). COX and cancer. QJM 98: 711-718 [Full Text]  
• Karlsson, P. C., Huss, U., Jenner, A., Halliwell, B., Bohlin, L., Rafter, J. J. (2005). Human Fecal Water Inhibits COX-2 in Colonic HT-29 Cells: Role of Phenolic Compounds. J. Nutr. 135: 2343-2349 [Abstract] [Full Text]  
• Gasparini, G., Gattuso, D., Morabito, A., Longo, R., Torino, F., Sarmiento, R., Vitale, S., Gamucci, T., Mariani, L. (2005). Combined Therapy with Weekly Irinotecan, Infusional 5-Fluorouracil and the Selective COX-2 Inhibitor Rofecoxib Is a Safe and Effective Second-Line Treatment in Metastatic Colorectal Cancer. The Oncologist 10: 710-717 [Abstract] [Full Text]  
• Yamaguchi, K., Lantowski, A., Dannenberg, A. J., Subbaramaiah, K. (2005). Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2. J. Biol. Chem. 280: 32569-32577 [Abstract] [Full Text]  
• Jones, D. H., Silberstein, P. T., Lynch, H., Ternet, C. (2005). Regression of Colorectal Adenomas With Intravenous Cytotoxic Chemotherapy in a Patient With Familial Adenomatous Polyposis. JCO 23: 6278-6280 [Full Text]  
• Reddy, B. S., Patlolla, J. M., Simi, B., Wang, S.H., Rao, C. V. (2005). Prevention of Colon Cancer by Low Doses of Celecoxib, a Cyclooxygenase Inhibitor, Administered in Diet Rich in {omega}-3 Polyunsaturated Fatty Acids. Cancer Res. 65: 8022-8027 [Abstract] [Full Text]  
• Cai, H., Al-Fayez, M., Tunstall, R. G., Platton, S., Greaves, P., Steward, W. P., Gescher, A. J. (2005). The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in ApcMin mice. Molecular Cancer Therapeutics 4: 1287-1292 [Abstract] [Full Text]  
• Choe, M. S., Zhang, X., Shin, H. J. C., Shin, D. M., Chen, Z. (2005). Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Molecular Cancer Therapeutics 4: 1448-1455 [Abstract] [Full Text]  
• Alhopuro, P., Alazzouzi, H., Sammalkorpi, H., Davalos, V., Salovaara, R., Hemminki, A., Jarvinen, H., Mecklin, J.-P., Schwartz, S. Jr., Aaltonen, L. A., Arango, D. (2005). SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer. Clin. Cancer Res. 11: 6311-6316 [Abstract] [Full Text]  
• Tong, C T, Howard, S A, Shah, H R, Van Quill, K R, Lin, E T, Grossniklaus, H E, O'Brien, J M (2005). Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br. J. Ophthalmol. 89: 1217-1220 [Abstract] [Full Text]